

Galapagos GLPG1690: ISABELA trials

| ISABELA1 | | | |
|----------------|-------------|----------|------------|
| Region | EEA/non-EEA | patients | recruiting |
| Australia | non-EEA | na | 3 |
| Belgium | EEA | ? | 0 |
| Chile | non-EEA | na | 0 |
| Czech Republic | EEA | 80 | 2 |
| Denmark | EEA | 15 | 3 |
| Finland | EEA | ? | 0 |
| Germany | EEA | 81 | 2 |
| Greece | EEA | ? | 3 |
| Peru | non-EEA | na | 0 |
| Spain | EEA | 88 | 8 |
| Taiwan | non-EEA | na | 1 |
| Turkey | non-EEA | na | 0 |
| United Kingdom | EEA | ? | 0 |
| United States | non-EEA | na | 15 |
| | | | |
| | | | |
| | all | 750 | 37 |
| | all EEA | 240 | 18 |
| | all non-EEA | 510 | 19 |

| ISABELA2 | | | |
|--------------------|-------------|----------|------------|
| Region | EEA/non-EEA | patients | recruiting |
| Argentina | non-EEA | na | 0 |
| Brazil | non-EEA | na | 0 |
| Canada | non-EEA | na | 1 |
| France | EEA | 63 | 4 |
| Germany | EEA | ? | 0 |
| Hungary | EEA | 29 | 4 |
| Israel | non-EEA | na | 6 |
| Italy | EEA | ? | 2 |
| Korea, Republic of | non-EEA | na | 5 |
| Mexico | non-EEA | na | 0 |
| Netherlands | EEA | 43 | 4 |
| New Zealand | non-EEA | na | 3 |
| Poland | EEA | 51 | 6 |
| South Africa | non-EEA | na | 0 |
| United States | non-EEA | na | 12 |
| | | | |
| | | | |
| | all | 750 | 47 |
| | all EEA | 185 | 20 |
| | all non-EEA | 565 | 27 |

| ISABELA 1+2 | |
|-------------|------------|
| patients | recruiting |
| 1500 | 84 |
| 425 | 38 |
| 1075 | 46 |

Last update: May 20, 2019

EEA = European Economic Area

patients: planned number of subjects, based on info of clinicaltrialsregister.eu (EEA only)

recruiting centers: currently recruiting, based on info of clinicaltrials.gov